Recent advances in endocrine therapy of breast cancer.
作者信息
Howell A, Dowsett M
机构信息
CRC Department of Medical Oncology, University of Manchester, Christie Hospital, NHS Trust.
出版信息
BMJ. 1997 Oct 4;315(7112):863-6. doi: 10.1136/bmj.315.7112.863.
Abstract
摘要
相似文献
1
Recent advances in endocrine therapy of breast cancer.
BMJ. 1997 Oct 4;315(7112):863-6. doi: 10.1136/bmj.315.7112.863.
2
New stars in the sky of treatment for early breast cancer.
N Engl J Med. 2004 Mar 11;350(11):1140-2. doi: 10.1056/NEJMe048037.
3
[Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
Bull Cancer. 2004 Dec;91(12):917-27.
4
[Tamoxifen and breast cancer: is everything known already?].
Tumori. 1998 Nov-Dec;84(6):A1-5.
5
6
Selecting adjuvant endocrine therapy for breast cancer.
Oncology (Williston Park). 2004 Dec;18(14):1733-44, discussion 1744-5, 1748, 1751-4.
7
Update on the current use of hormonals as therapy in advanced breast cancer.
Anticancer Drugs. 2003 Apr;14(4):265-73. doi: 10.1097/00001813-200304000-00003.
8
[Aromatase inhibitors in the adjuvant therapy of breast cancer].
Gynakol Geburtshilfliche Rundsch. 2005 Jun;45(3):132-6. doi: 10.1159/000085193.
9
Aromatase inhibitor development and hormone therapy: a perspective.
Semin Oncol. 2003 Aug;30(4 Suppl 14):12-22. doi: 10.1016/s0093-7754(03)00303-8.
10
Aromatase inhibitors for the treatment of breast cancer: is tamoxifen of historical interest only?
J Natl Cancer Inst. 2006 Sep 20;98(18):1261-3. doi: 10.1093/jnci/djj387.
引用本文的文献
1
Preparation and Characterization of Chitosan and Inclusive Compound-Layered Gold Nanocarrier to Improve the Antiproliferation Effect of Tamoxifen Citrate in Colorectal Adenocarcinoma (Caco-2) and Breast Cancer (MCF-7) Cells.
Turk J Pharm Sci. 2022 Aug 31;19(4):391-399. doi: 10.4274/tjps.galenos.2021.48961.
2
A Case of Complete Response to Letrozol Treatment in a Postmenopausal Woman With Breast Cancer Who has Progressed After Multiple Lines of Chemotherapy.
World J Oncol. 2013 Feb;4(1):58-60. doi: 10.4021/wjon628w. Epub 2013 Mar 6.
3
Exostosin 1 regulates cancer cell stemness in doxorubicin-resistant breast cancer cells.
Oncotarget. 2017 Jul 31;8(41):70521-70537. doi: 10.18632/oncotarget.19737. eCollection 2017 Sep 19.
4
Trends in 1-year survival of people admitted to hospital in Ontario, 1994-2009.
CMAJ. 2013 Nov 5;185(16):E755-62. doi: 10.1503/cmaj.130875. Epub 2013 Sep 30.
5
Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study.
Breast Cancer Res. 2012 Apr 4;14(2):R57. doi: 10.1186/bcr3161.
6
Adjuvant Endocrine Therapy in Premenopausal Patients.
Breast Care (Basel). 2008;3(5):311-316. doi: 10.1159/000156985. Epub 2008 Oct 17.
7
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Cochrane Database Syst Rev. 2009 Oct 7;2009(4):CD003370. doi: 10.1002/14651858.CD003370.pub3.
8
Has tamoxifen had its day?
Breast Cancer Res. 2002;4(6):213-7. doi: 10.1186/bcr536. Epub 2002 Aug 27.
9
Tamoxifen resistance in breast cancer: elucidating mechanisms.
Drugs. 2001;61(12):1721-33. doi: 10.2165/00003495-200161120-00004.
10
Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial.
Br J Cancer. 2001 Aug 3;85(3):317-24. doi: 10.1054/bjoc.2001.1925.
Zotero 插件